bioRxivPharmacology & Toxicology
Chidamide decreases c-MET mRNA methylation and in turn increases the sensitivity of non-small cell lung cancer to crizotinib
Abstract
IntroductionCrizotinib is a kinase inhibitor targeting c-MET/ALK/ROS1 used as the first-line chemical for the treatment of non-small cell lung cancer (NSCLC) with ALK mutations. Although c-MET is frequently overexpressed in 35-72% of NSCLC, most NSCLCs are primarily resistant to crizotinib treatment. MethodA set of NSCLC cell lines were used to test the effect of chidamide on the crizotinib sensitivity in vitro and in vivo. Relationships between the synergistic effect of chidamide and c-MET expression and RNA methylation were systemically studied with a battery of molecular biological assays. ResultsWe found for the first time that chidamide could increase the crizotinib sensitivity of a set of ALK mutation-free NSCLC cell lines, especially those with high levels of c-MET expression. Notably, chidamide could not increase the crizotinib sensitivity of NSCLC cells cultured in serum-free medium without hepatocyte growth factor (HGF; a c-MET ligand). In contrast, the addition of HGF into the serum-/HGF-free medium could restore the synergistic effect of chidamide. Moreover, the synergistic effect of chidamide could also be abolished either by treatment with c-MET antibody or siRNA-knockdown of c-MET expression. While cells with low or no c-MET expression were primarily resistant to chidamide-crizotinib cotreatment, enforced c-MET overexpression could increase the sensitivity of these cells to chidamide-crizotinib cotreatment. Furthermore, chidamide could decrease c-MET expression by inhibiting mRNA N6-methyladenosine (m6A) modification through the downregulation of METTL3 and WTAP expression. Chidamide-crizotinib cotreatment significantly suppressed the activity of c-MET downstream molecules. Conclusionchidamide downregulated c-MET expression by decreasing its mRNA m6A methylation, subsequently increasing the crizotinib sensitivity of NSCLC cells in a c-MET-/HGF-dependent manner. GRAPHIC SUMMARY O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=126 SRC="FIGDIR/small/012971v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@5a81d4org.highwire.dtl.DTLVardef@19f1forg.highwire.dtl.DTLVardef@75d74forg.highwire.dtl.DTLVardef@8a9f77_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SIRT2, TFEB, CNIH3, ADRM1, AND TM9SF4 AS POTENTIAL BIOMARKERS OF RESISTANCE TO CRIZOTINIB AND POOR PROGNOSIS IN LUNG ADENOCARCINOMA: IMPLICATIONS FOR TARGETED THERAPY AND IMMUNOTHERAPY
Edgar Villena-Macia, Maissaa Bouchakour-Bouchaqor, … Eva María Galán‐Moya·bioRxiv·Jul 10, 2025
- mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion
Claudia Gentile, William W. Feng, … Cigall Kadoch·bioRxiv·Mar 1, 2026
- Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer
J. K. Rotow, P. Gui, … C. M. Blakely·bioRxiv·May 24, 2019
- Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response
Kassandra J. Naughton, Xiulong Song, … Christine F. Brainson·bioRxiv·Jun 25, 2024
- MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
S. Ramesh, A. Cifci, … A. M. Baschnagel·bioRxiv·Oct 26, 2023
- SDF-1/CXCR4 inhibition prevents paradoxical generation of cisplatin-induced pro-metastatic niches
G. Bertolini, V. Cancila, … L. Roz·bioRxiv·Oct 26, 2020